Myeloid malignancies, and particularly myeloproliferative neoplasms (MPN), represent a dynamic spectrum of clonal disorders shaped by genetic, epigenetic and microenvironmental forces. This collection brings together original research and reviews that illuminate the evolving biology, clinical heterogeneity and therapeutic vulnerabilities of these diseases. From pioneering insights into JAK2-driven signaling, hypoxia responses and stromal niche remodeling, to emerging concepts in clonal evolution, inflammation, epigenetics and immune dysregulation, these studies highlight the complex interplay between malignant clones and their ecosystem. The articles further address pressing clinical challenges, including refined risk stratification in genetically defined subgroups, thrombotic risk prediction, disease progression, and therapy-related myeloid neoplasms. Advances in genomic profiling, novel model systems and targeted therapeutic approaches underscore a rapidly changing landscape. Collectively, this collection provides a timely and integrative perspective on MPN and related myeloid cancers, bridging mechanistic discovery with translational relevance and paving the way toward more precise and effective patient care.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the therapeutic landscape of hematological malignancies. Built on decades of progress in immunology, cellular engineering, and translational research, CAR-T cell therapies targeting antigens such as CD19 and BCMA have demonstrated deep and durable remissions in several B-cell malignancies and are now established as standard of care in defined clinical settings. These successes represent one of the most significant advances in hematological oncology in recent years. Despite this progress, substantial challenges remain. Not all malignancies are equally amenable to CAR-T cell approaches, and several hematological cancers continue to be difficult to target due to antigen heterogeneity, lineage plasticity, immune escape, and an immunosuppressive tumor microenvironment. In addition, as CAR-T therapy is moved into earlier lines of treatment and offered to broader patient populations, new complexities are emerging. Increased exposure has highlighted a spectrum of toxicities, including cytokine release syndrome and immune effector cell–associated neurotoxicity, as well as rarer but potentially life-threatening complications. Understanding, predicting, and mitigating these adverse effects has become an urgent priority. At the same time, rapid innovation continues. Advances in CAR design, manufacturing, and delivery along with the development of dual-targeting strategies, allogeneic products, and novel in vivo CAR platforms are reshaping expectations of what cellular therapies may achieve. Rigorous evaluation of long-term outcomes, mechanisms of resistance, and real-world implementation is now essential to guide the next phase of clinical translation. This collection brings together a series of articles that reflect on the remarkable achievements of CAR-T cell therapy while critically examining the biological, clinical, and logistical challenges that lie ahead. Together, these contributions provide a timely overview of the field, highlighting both the promise of CAR-T cell therapies and the work still required to extend their benefits safely and effectively to more patients.

In this collection we highlight a selection of articles from 2025, which top the list of the journal’s most cited, downloaded and most shared (including press coverage, blogs, X, Facebook and Weibo). The articles showcase the breadth of scope and coverage that the journal consistently delivers to its readers.

In this collection we highlight a selection of articles from 2024, which top the list of the journal’s most cited, downloaded and most shared (including press coverage, blogs, Twitter, Facebook and Weibo). The articles showcase the breadth of scope and coverage that the journal consistently delivers to its readers.

The immediate goal of Chronic Myeloid Leukemia (CML) therapy, operational cure, is defined as survival like sex- age-adjusted normals and a normal quality-of-life (QoL). This is being met in many people with CML receiving tyrosine kinase-inhibitor (TKI) drugs. More ambitious goals are achieving a normal life expectancy off therapy, referred to as therapy-free remission (TFR) and ultimately permanent eradication of the disease. Unfortunately, TFR is achieved in only 10-20 percent of people with CML, whilst the first goal is being met in many people with CML but a normal life-expectancy off therapy is achieved in very few, and permanent eradication of the disease in none. CML therapy recommendations are continuously modified with success: 10-year survival is now 80–90% in clinical trials, with about one-half of deaths from causes unrelated to CML. People achieving a stable deep molecular response (DMR) can discontinue therapy with about one-half achieving long-term TFR. The clinical advantage of TFR over lifelong TKI-therapy is obvious, but the road to achieving this goal is complex, expensive and not open to many. There is controversy on how to best use TKIs. Which are the best and most cost-effective strategies to achieve TFR, to optimize survival and improve QoL? What strategy is best in someone not meeting proposed TKI-response or -stopping criteria or fails because of molecular, cytogenetic and/or hematologic leukemia recurrence? How can we reduce adverse events from lifelong TKI-therapy and complications of more intensive therapies aimed at achieving TFR? The main issues are which TKI, at what dose, for how long and alone or with other drugs? A major issue in CML research is the role of BCR::ABL1 independent pathways resulting in molecular and/or cytogenetic clonal evolution. Blast phase CML is characterized by additional molecular aberrations. The best therapy of blast phase disease is controversial and it is best prevented. With this collection on CML related publications, we try to summarize current knowledge and address the most relevant research questions. You are invited to contribute to this collection with up-to-date results from your research.

Increased understanding of the phenotype and genotype abnormalities associated with cancer including cytogenetic, immune and molecular features has facilitated development of tests to identify and quantify residual cancer cells not detected by conventional methods. Progress is especially rapid in haematological compared with solid cancers. Starting from modestly accurate tests for measurable residual disease (MRD), testing is being used at many centres and available from commercial laboratories. It is hoped that results of these tests will provide clinically meaningful predictive and/or prognostic data and inform therapy decision-making. This collection of articles on MRD features critical analyses of the extent to which these goals have been achieved in haematological and solid cancers.

In this collection we highlight a selection of articles from 2023, which top the list of the journal’s most cited, downloaded and most shared (including press coverage, blogs, Twitter, Facebook and Weibo). The articles showcase the breadth of scope and coverage that the journal consistently delivers to its readers.

The Emerging Leaders collection welcomes and recognizes new talent in the hematology field. This collection acknowledges groundbreaking researchers, clinicians, and educators who are still in the early stages of their scientific careers, serving as a platform to showcase their latest work.

In this collection we highlight a selection of articles from 2022, which top the list of the journal’s most cited, downloaded and most shared (including press coverage, blogs, Twitter, Facebook and Weibo). The articles showcase the breadth of scope and coverage that the journal consistently delivers to its readers.

In line with the UN Sustainable Development Goal to Reduce Inequalities (SDG10), this collection aims to bring together articles enhancing our understanding of cancer health disparities across the different dimensions of inequality research. There are many expanding fields of health inequalities research but this collection will include articles examining disproportionate cancer burdens in populations such as: rural-urban, gender/sexual, racial/ethnic, religious minority and socioeconomic status groups, and of course any group where health inequality needs to be addressed. This wider collection builds upon our existing collections more specifically focused on Racial and ethnic disparities in cancer and Racial and ethnic disparities in cancer in the US We are building an ongoing knowledge base of content from across all oncology journals to increase the discoverability of articles in this important research area. Thus, we call for new contributions to this collection and invite you to read recent research below.

This collection is dedicated to the impact of the COVID-19 pandemic in cancer healthcare. We are particularly interested in research examining the long-term impact for patients with cancer. To increase the discoverability of scientific literature related to COVID-19 cancer research, here we bring together key articles from across a series of oncology journals. We welcome future submissions to expand this collection further.

The World Health Organization (WHO) Classification of Tumours provides a definitive classification of all tumours, worldwide. This is essential to underpin the diagnosis and treatment of cancer, as well as research and education. Without it, clinical trial results could not be compared between countries, research results could not be evaluated collectively and epidemiological studies based on cancer registration would be impossible. The classification will help move the field forward by being based on a forwardlooking multidisciplinary effort grounded in genetic advances, with an eye on worldwide applicability. An overview of the classification and its salient features are provided in two typescripts, which cover the classification of myeloid and histiocytic/dendritic neoplasms and the classification of lymphoid neoplasms. Added to this is the recent 'HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions'. In this typescript a group of experts under auspices of the Human Genome Organization’s (HUGO) Gene Nomenclature Committee (HGNC) proposes using double colons (::) as the official designation for fusion genes. The Leukemia Editors strongly support the HGNC recommendation and request authors use the HGNC nomenclature in submissions to Leukemia and other journals. The goal of HUGO and HGNC is to provide unique symbols and names for human gene loci including protein coding genes, non-coding RNA genes and pseudogenes with the purpose of unambiguous scientific communication.